Targeting ZMIZ1 induces differentiation in acute myeloid leukemia via chromatin remodeling
Blocking a newly identified protein pushes leukemia cells toward maturity and death in mice, nominating a fresh drug target beyond current treatments.
Through a CRISPR-Cas9 screen, ZMIZ1 was identified as a novel transcriptional co-regulator enforcing differentiation blockade in AML, with its ablation inducing terminal differentiation and prolonging survival in murine models via a phase-separated super-enhancer mechanism. Small molecule candidates targeting ZMIZ1 demonstrate potent in vivo and organoid efficacy, nominating ZMIZ1 as a promising therapeutic target for AML differentiation therapy beyond APL.
What the study was
- Study design
- Preclinical: CRISPR screen, murine AML models, AML organoids, small compound development
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Signal Transduct Target Ther
Why it surfaced
High-novelty AML target discovery (ZMIZ1) in top-tier journal with compelling mechanistic and in vivo data plus small molecule candidates. Score capped at 5 per non-human studies rule; warrants tracking to clinical-stage development.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.